Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Gross Profit (2016 - 2025)

Historic Gross Profit for Fortress Biotech (FBIO) over the last 11 years, with Q3 2025 value amounting to $11.9 million.

  • Fortress Biotech's Gross Profit rose 1691.28% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.1 million, marking a year-over-year decrease of 434.48%. This contributed to the annual value of $36.8 million for FY2024, which is 4028.56% down from last year.
  • As of Q3 2025, Fortress Biotech's Gross Profit stood at $11.9 million, which was up 1691.28% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Gross Profit ranged from a high of $28.3 million in Q3 2023 and a low of $6.0 million during Q1 2023
  • Its 5-year average for Gross Profit is $11.1 million, with a median of $9.9 million in 2021.
  • In the last 5 years, Fortress Biotech's Gross Profit skyrocketed by 20431.93% in 2023 and then crashed by 6413.52% in 2024.
  • Quarter analysis of 5 years shows Fortress Biotech's Gross Profit stood at $8.8 million in 2021, then decreased by 0.74% to $8.7 million in 2022, then skyrocketed by 103.75% to $17.7 million in 2023, then crashed by 41.01% to $10.4 million in 2024, then grew by 13.75% to $11.9 million in 2025.
  • Its Gross Profit stands at $11.9 million for Q3 2025, versus $11.5 million for Q2 2025 and $8.3 million for Q1 2025.